Dienogest for Treatment of Adenomyotic Uteri

Learn more about:
Related Clinical Trial
Determination of the Incidence of Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome, or the Incidence of Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis The Effect of Adenomoyosis on Pregnancy Outcomes Observational Study of Patients Suffering From Endometriosis and Adenomyosis Factors Associated With Adenomyosis and a Clinical Scoring System for the Diagnosis Quality of Life After Hysterectomy (AdenoQOL) Low Molecular Weight Heparin on the Adenomyosis Patients’IVF-ET Outcome Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI Clinical and Molecular Study of Endometriosis and Adenomyosis Surgical Success After Laparoscopic vs Abdominal Hysterectomy Electronic Catheter Stethoscope Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Uterine Artery Embolization for Symptomatic Fibroids Oxytocin in MRI-HIFU To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Effect of Addition of Steroids on Duration of Analgesia Paracervical Block in Laparoscopic Hysterectomy Use of Dexamethasone in Uterine Artery Embolization Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Dienogest for Treatment of Adenomyotic Uteri Health-Related QoL Among Women Receiving Hysterectomy in NTUH Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis Adenomyosis and Ulipristal Acetate Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis LNG-IUS for Treatment of Dysmenorrhea Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Adenomyosis: Genomic Mechanisms and Biological Response What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Comparing Efficacy of Microwave vs Embolization Treatment for Adenomyosis Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis A Prospective Study of Diagnostic Accuracy of Ultrasound Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis A Multi-omics Study of Adenomyosis Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis Levonorgestrel Intrauterine System and Adenomyosis Validation of the Adenomyosis Calculator Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Norwegian Adenomyosis Study III: Peristalsis Histopathological Diagnosis of Adenomyosis Norwegian Adenomyosis Study I Vaginal Bromocriptine for Treatment of Adenomyosis Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis

Brief Title

Dienogest for Treatment of Adenomyotic Uteri

Official Title

Dienogest Versus a Low-dose Combined Oral Contraceptive for Treatment of Adenomyotic Uteri

Brief Summary

      Adenomyosis is a common disease in women aged 40-50 years. It associates with dysmenorrhea
      and menorrhagia. Hysterectomy was considered the main treatment that could definitively cure
      this disease. Other treatment options are increasingly offered, including hormonal
      suppression with gonadotropin-releasing hormone agonists or danazol and endometrial ablation.
      However, deep adenomyosis responds weakly to the above treatment options, which are commonly
      not considered for long-term management because of the associated side effects.

      Dienogest is a progestin medication which is used in birth control pills and in the treatment
      of endometriosis and adenomyosis. Low-dose combined oral contraceptive (COC) pills have been
      widely used as the primary treatment for menorrhagia. COCs can also be used to induce
      endometrial atrophy and to decrease endometrial prostaglandin production, which can
      consequently improve menorrhagia and dysmenorrhea that are associated with adenomyosis
    



Study Type

Interventional


Primary Outcome

Number of women who will improved from the pelvic pain measured by visual analogue scale

Secondary Outcome

 Uterine volume (cm 3 ) measure by ultrasound

Condition

Adenomyosis

Intervention

Dienogest group

Study Arms / Comparison Groups

 Dienogest group
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

100

Start Date

March 1, 2019

Completion Date

August 1, 2020

Primary Completion Date

July 1, 2020

Eligibility Criteria

        Inclusion Criteria:

          -  Women aged 20-40 years

          -  Women with ultrasonographic evidence of adenomyosis

          -  Woman complains of vaginal bleeding or pelvic pain related to adenomyosis

        Exclusion Criteria:

          -  Women with a history of malignancy or histological evidence of endometrial hyperplasia

          -  any adnexal abnormality on ultrasound

          -  undiagnosed vaginal

          -  contraindication to receive Vissane or gynera .
      

Gender

Female

Ages

20 Years - 40 Years

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

Egypt

Location Countries

Egypt

Administrative Informations


NCT ID

NCT03890042

Organization ID

DAD


Responsible Party

Principal Investigator

Study Sponsor

Assiut University


Study Sponsor

, , 


Verification Date

August 2020